Investor Presentation
Released
Released
Announcement PDF
(ASX:EMD)
A clinical stage biotech,
informed by the patient
experience, focused on
unmet needs in neuroscience
and mental health
February 2023
Company Overview
DISCLAIMER
This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or
recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only
and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the
information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and
needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates,
opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or
implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation.
Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To
the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including
without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything
contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown
risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The
distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe
any such restrictions.
This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of
Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's
current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of
building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties
and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in
the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the
view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are
made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated
events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Presentation release authorised by Michael Winlo, CEO and Managing Director
Emyria 2023
2
MDMA & PSILOCYBIN NOW RECOGNISED AS “MEDICINES” BY TGA
“For approval to prescribe, psychiatrists will
need to demonstrate appropriate training,
patient selection, evidence-based treatment
protocols and patient monitoring.
Further, ongoing psychotherapeutic support
remains an essential component of the
psychedelic treatment model.”
-RANZCP (College of Psychiatrists)
&
Emyria 2023
3
CLINICAL
FOCUS
COMPARATIVE
ADVANTAGES
Advancing
MDMA & CBD to
address unmet
needs in CNS and
Mental Health
LEADING
PROGRAMS
& TRACTION
Tenmile = Health-focused investment
fund of the Forrest Family
●
●
●
●
●
●
Strong register - Tenmile1 7.8% / Directors 27% / Top 50 70+%
Proprietary Real-World Data - informs clinical development
Front-line clinical delivery (Emerald Clinics) - provides patient access
Unique Ultra-Pure CBD formulations - delivers clinical advantages
Novel MDMA-inspired chemical entities - substantial preclinical assets
Global leadership team & partners with drug registration successes
ULTRA-PURE CANNABINOID MEDICINES
●
First dose form (EMD-RX5) in Phase 3 clinical trials (ACTRN: 12622001319763)
●
Proprietary “RX” formulation high bioavailability, safety & tolerability,
consistent release of cannabinoid-based medicines
●
Multiple global drug registration opportunities; FDA-compliant formulation
MDMA-INSPIRED MEDICINES
●
One of world’s largest libraries of unique entities inspired by MDMA
developed in partnership with University of Western Australia
●
TGA accepts MDMA as Schedule 8; positioned to lead MDMA-assisted
therapy delivery in Australia via specialist partner network
( EMD : ASX )
1
Neuroscience & Mental Health
IP &
PROTECTION
Growing patent library covering novel formulations, methods
of treatment and new chemical entities
HIGHLIGHTS OF
BUSINESS STRUCTURE | & ASSETS
CARE
DATA
TREATMENTS
ULTRA-PURE CBD
Specialist cannabinoid clinics
deliver care for 1,000’s of patients
across Australia for a wide range
of clinical indications.
EMD-RX5 (low-dose, synthetic CBD for
over-the-counter indications) IN PHASE 3
EMD-RX7 (high-dose synthetic CBD for
prescription indications SCOPING PHASE 1
REAL-WORLD DATA
With the TGA rescheduling of
MDMA and psilocybin, Emyria
is establishing a network of
specialists to support
psychedelic-assisted therapy
Supports development of
novel treatments
MDMA-INSPIRED THERAPIES
ADVANCED MDMA ANALOGUE LIBRARY being
developed with the University of Western Australia.
Pursuing faster-MDMA, and treatments for
movement disorder IN PRECLINICAL SCREENING
Emyria 2023
EMYRIA’S MODEL DE-RISKS & ACCELERATES DRUG DISCOVERY
TRADITIONAL DRUG DEVELOPMENT (costly, time-intensive, high-risk)
Discovery
Target
Validation
Lead
Optimisation
Preclinical
Development
Phase 1
Clinical Trial
Phase 2
Clinical Trial
Phase 3
Clinical Trial
7% success
25% success
EMYRIA’S DRUG DEVELOPMENT APPROACH (Gather insights with patients to de-risk & accelerate drug development)
Discovery &
Preclinical
Validation
Dose form
Innovation
Phase 1/2
Clinical trial
Real-World Data insights from 8,000+ patients
Ultra-Pure Cannabinoids
MDMA analogues
FDA
Registration
RX7
Phase 2/3
Clinical trial
time
FDA
Registration
Informs indication selection and trial design
RX5
Emyria 2023
6
LEADERSHIP | GLOBAL DRUG DEVELOPMENT & COMMERCIALISATION SUCCESSES
Dr Stewart Washer
Executive Chairman
PhD (Microbiology)
Prof Sir John Tooke
Non-Executive Director &
Chair of the Risk Committee
Dr Karen Smith
Executive Director
MD, PhD, MBA, LLM
FRCP, FMedSci
● Emyria founder, largest shareholder
● Founded multiple ASX companies
● Multiple trade sales
● Knighted for services to medicine
● Clinician researcher - past President AMS
● Advisor to NHS on “learning health systems”
● Experienced biopharma C-suite exec
● Overseen 20+ FDA approvals
● Multiple, $B+ M&A completions
(Acq. $1B)
Dr Michael Winlo
CEO & Managing Director
MBBS(Hons), MBA (Stanford)
● Data, trials and drug development
● Paper-to-digital at Linear
● Founding five, Palantir Health Team
C/Prof Alistair Vickery
Medical Director
MBBS, FRACGP, FCHSM
● Big Data researcher, epidemiology
● Chair of Black Swan Health
● Professor of Medicine at UWA
Matt Callahan
Non-Executive Director
LLB
● 4 FDA approvals
● Venture capital experience
● Successful exit - iCeutica to Iroko
ADVANCED
CANNABINOID
DEVELOPMENT
Emyria 2023
8
EPIDYOLEX™ | WORLD’S ONLY REGISTERED CBD OIL > $1B / YR SALES
Despite hundreds of CBD products available, only 1 product has demonstrated the clinical effectiveness and product reliability
required to achieve registration with major global regulators (like the FDA), driving significant value for shareholders
1998
GW Pharma invests >$2B &
>50 clinical trials [1]
2018
FDA approves Epidyolex as
“small molecule” [2]
2021
GW acquired by Jazz Pharma
for USD $7.2B [3]
KEY INSIGHTS
(1) Drug registration creates value but, requires
(2) Great evidence (Real-World Data) and
(3) Great products (Ultra-Pure cannabinoids)
We believe emyria can improve on Epidyolex oil
& accelerate multiple new drug registrations
1. https://www.europeanpharmaceuticalreview.com/news/152570/highest-british-business-award-goes-to-cannabis-drug-developer-gw-pharmaceuticals/
2. GW Pharmaceuticals Annual Report June 2018
3. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-gw-pharmaceuticals-plc-creating
Emyria 2023
9
MOST CANNABINOID PRODUCTS HAVE LIMITATIONS
CBD PRODUCTS ARE
UNDIFFERENTIATED
PRODUCT RELIABILITY
IS VARIABLE [1]
BIOAVAILABILITY
IS POOR [2]
There are more than
What’s
on the
label is
not in
the box
250
products in Australia,
most are undifferentiated.
KEY OPPORTUNITY
100mg
Your body
absorbs ~6.5%
of what is
taken orally
Food
dramatically
affects
absorption
6.5mg
(6.5%)
Emyria has developed a differentiated cannabinoid product that is:
1. Ultra-Pure (meets requirements for FDA registration) 2. improves bioavailability in a 3. patient-preferred dose form.
1. Johnson, E., Kilgore, M. & Babalonis, S. Label accuracy of unregulated cannabidiol (CBD) products: measured
concentration vs. label claim. J Cannabis Res 4, 28 (2022). https://doi.org/10.1186/s42238-022-00140-1
2. https://www.tga.gov.au/sites/default/files/auspar-cannabidiol-210115.pdf
Emyria 2023
10
IMPROVING CBD
THE EMD-RX PLATFORM
A world-first, proprietary formulation of synthetically-derived
Ultra-Pure cannabidiol in a capsule with high bioavailability to
support multiple, global, over-the-counter & prescription
registration opportunities.
EMD-RX PLATFORM
CLINICAL ADVANTAGES OVER INCUMBENTS
EMD-RX
PATIENT PREFERRED FORM
ULTRA PURITY
SAFE & TOLERABLE
NOVEL IP
FDA-READY
PREFERRED DOSING PROFILE
AT CLINICAL STAGE
KEY INSIGHT
Vs
CBD oils
& similar preparations
Convenient, solid oral capsules (no spilling)
Majority of products are oil preparations
No detectable THC
No detectable impurities
Small quantities of THC
Small quantities of impurities
Safe & well tolerated at trial doses
No observed gastrointestinal upset
Adverse events at higher doses (eg GI upset)
Proprietary formulation
FDA Drug Master File for API.
Allows Emyria to reference material to regulator
without disclosing contents [1]
Most CBD oils are “me too” products with generic
formulations and limited IP protections
Most CBD oils do not meet FDA requirements for CBD
purity (with exception of Epidyolex) [2]
High bioavailability, low inter-patient
variability & slow release
Poor bioavailability, high patient variability
In Phase 3 clinical trials
Majority of products have no supportive trial data
Emyria’s proprietary, FDA-ready dose form solves a number of limitations with common CBD preparations.
EMD-RX5 is ready for multiple indications and global registration opportunities with demonstrated clinical performance.
www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs
www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
Emyria 2023
12
EMD-RX5
Emyria’s first Ultra-Pure, low-dose CBD capsule
In Phase 3 trials and pursuing multiple,
global “over-the-counter” registration opportunities
PSYCHOLOGICAL DISTRESS IN AUSTRALIA - FIRST INDICATION FOR EMD-RX5
INITIAL CLINICAL OPPORTUNITY
NO OTC SOLUTION CURRENTLY EXISTS BUT,
CANNABIDIOL MAY HELP:
2.8M
Adults with
Chronic Pain
1.4M
Of these, 1.4M
with
have symptoms
symptoms
of
of
Anxiety
anxiety1 or or
Stress
stress
Psychological distress comprises symptoms of anxiety, stress, sleep disturbance
and GI upset with a higher prevalence in patients with chronic disease
Mean anxiety score
Emyria’s proprietary Real-World Data on hundreds of patients
receiving low-dose CBD for 6+ months has informed our
choice of target population and clinical indication.
Treatment duration (in days)
●
TGA allows low-dose CBD (<150mg/day) to be registered as an “over-the-counter”, pharmacist-only, Schedule 3 (S3) medicine. [2]
●
Registered S3 (OTC) treatments do not require a doctor’s prescription. Australians spend $5b/year on OTC medicines [3]
●
150mg of CBD currently costs between $250 and $800 per month. All out-of-pocket. Large opportunity to develop an affordable OTC, CBD medicine.
●
Emyria has multiple ‘methods of use’ patents to cover use of low-dose CBD across a range of appropriate indications.
1. National Study of Mental Health and Wellbeing 2020-21 series, Australian Bureau of Statistics
2. See ASX announcement 16 December 2021 3. Medicines in the health system, Australian Institute of Health and Welfare (2022)
Emyria 2023
14
EMD-RX5 | ULTRA-PURE CBD CAPSULE VS EPIDYOLEX™ OIL
In a key, head-to-head study, EMD-RX5 was safe, well tolerated and demonstrated:
(1) high bioavailability (2) slow release profile (3) lower dose variability and
EMD-RX5 pursuing registration with TGA:
In active Phase 3 clinical trials
due to complete H2, 2023
Ultra Pure CBD with a Drug Master File (DMF)
allows assessment as “small molecule” with FDA after
TGA registration
Suitable for multiple registration opportunities
Ready for indication, and geographic, expansion
Emyria 2023
15
WHAT’S NEXT? | GROW MARKET FOR EMD-RX5 (ADD INDICATIONS, EXPAND GEOGRAPHY)
An Ultra-Pure cannabinoid product makes it possible to pursue registration beyond Australia in jurisdictions where product purity
rules are stricter. With the support of Emyria’s proprietary Real-World Data, EMD-RX5 has multi-indication potential.
Emyria’s Ultra-Pure dose
form & Real-World Data
supports growth
through indication and
geographic expansion.
1. See ASX announcement 16 December 2021 2. Canavan, C., West, J. and Card, T., 2014. The epidemiology of irritable bowel syndrome. Clinical epidemiology, 6, p.71.
3.Grandner, M.A., Martin, J.L., Patel, N.P., Jackson, N.J., Gehrman, P.R., Pien, G., Perlis, M.L., Xie, D., Sha, D., Weaver, T. and Gooneratne, N.S., 2012. Age and sleep
Emyria 2023
disturbances among American men and women: data from the US Behavioral Risk Factor Surveillance System. Sleep, 35(3), pp.395-406.
4. National Study of Mental Health and Wellbeing 2020-21 series, Australian Bureau of Statistics
16
WHAT’S NEXT? | LAUNCH PRESCRIPTION-STRENGTH CBD (EMD-RX7)
Chart shows concentrations of CBD in
the blood for 3 different formulations as
measured over a 24 hour period in an
animal model.
Each formulation compared the same
amount of CBD - 50mg.
EMD-RX7 showed more than 4 times
the bioavailability of Epidyolex and is
now being prepared for Phase 1 clinical
trials to support prescription indications
where higher doses of Ultra-Pure CBD
are indicated. [1]
Emyria has been accepted into the
NIH’s preclinical screening platform
for pain (PSPP) to further evaluate
EMD-RX7 for pain indications. [2]
Additional, FDA-focused indications are
in planning via 505(b)2 pathway.
KEY INSIGHT
HIGHER BIOAVAILABILITY CBD has potential to support multiple, global prescription registrations
1. See ASX announcement 17 March 2022
2. See ASX announcement 28 November 2022
Emyria 2023
17
WHAT’S NEXT? | ADVANCED CANNABINOID DEVELOPMENT
DRUG DEVELOPMENT
H1 2023
H2 2023
Steps
Over The Counter
pivotal Phase 3
clinical trial for EMD-RX5 to
support TGA registration
TGA-APPROVAL
TGA dossier preparation
and submission
Phase 3 clinical trial
- INDICATION EXPANSION
- COMMERCIALISATION
- GLOBAL PARTNERSHIPS
JULY 2023
Prescription
Complete preclinical
screening & Phase 1 trial of
EMD-RX7 to support
prescription opportunities
Phase 1 clinical trial
New registration
programs TBD
has been accepted into the NIH’s preclinical screening program for pain.
This is a fully funded program. See ASX release 28 Nov 2022
Emyria 2023
18
MDMA-INSPIRED
THERAPY INNOVATION
Emyria 2023
19
POST-TRAUMATIC STRESS DISORDER
AUSTRALIA
USA
10M
1M
US$232B
Total economic burden [1]
with
PTSD [2]
1.4M
with
Up to 500K
symptoms
of
“Treatment
anxiety
or
Resistant”
stress
US$25,684 annual cost of PTSD per military personnel
and veterans, (versus US$18,640 per civilian)
1. https://www.psychiatrist.com/jcp/trauma/ptsd/economic-burden-posttraumatic-stress-disorder-united-states-societal-perspective/
2. https://www.phoenixaustralia.org/research/research-publications/
Emyria 2023
20
MDMA-ASSISTED THERAPY FOR PTSD | PROMISING RESULTS
Treatment response and remission for MDMA and Placebo groups as a percentage
of total participants randomised to each arm (MDMA, n = 46; Placebo, n= 44).
In a landmark Phase 3 study (n=91) [1], patients with PTSD
(average of 15 years severe illness) were randomised to
receive MDMA-assisted therapy or therapy with placebo.
67% Of participants in the MDMA group
no longer met the PTSD diagnosis criteria
following 3 sessions of MDMA-assisted therapy,
compared to 32% in the therapy-only group.
MAPS has recently
completed a
second Phase 3 and
is preparing for
FDA registration. [3]
1. Trial of MDMA-assisted therapy for severe PTSD, Multidisciplinary Association for Psychedelic Studies (MAPS), 2021
2. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. 2021 Jun;27(6):1025-33
3. https://mapspublicbenefit.com/press-releases/mapp2-completion-announcement/
Emyria 2023
21
MDMA & PSILOCYBIN NOW RECOGNISED AS “MEDICINES” BY TGA
“For approval to prescribe, psychiatrists will
need to demonstrate appropriate training,
patient selection, evidence-based treatment
protocols and patient monitoring.
Further, ongoing psychotherapeutic support
remains an essential component of the
psychedelic treatment model.”
-RANZCP (College of Psychiatrists)
Assisting psychiatrists prepare is a HUGE CHALLENGE to patient access
emyria is uniquely positioned to create value in this new regulatory environment via:
(1) Facilitating Patient Delivery
& (2) Novel Drug Discovery
Emyria 2023
22
1) SUPPORT PATIENT DELIVERY
Drug
Manufacturers
GMP Manufacturing
MDMA-INSPIRED MEDICINES
Emyria is uniquely resourced to bridge the gap
to facilitate psychedelic-assisted therapy
● Scheduled Drug Importation
● Drug Procurement
Community
Psychiatrists
Specialist Training
Patient Selection
Consulting Suites
● Care Plan Design
● Authorised Prescriber Support
PATIENTS
● Care Delivery
Therapy Training
Skill Development
Data Gathering and Reporting
Packaging these services creates a scalable opportunity
for generating licence revenues AND Real-World Data
that can improve Emyria’s MDMA analogue program
5,000
patients
Emyria 2023
23
MDMA-INSPIRED MEDICINES
2) CREATE “NEXT-GENERATION” MDMA
MDMA is a small, stable, brain-penetrating molecule that
increases the release of 3 primary neurotransmitters
Serotonin
thought to contribute
to feelings of well-being
Dopamine
associated with feelings of
pleasure and satisfaction
Noradrenaline
affects attention and related
to “fight or flight” response
MDMA has many points of diversification creating opportunities to tune selectivity for key
neurotransmitters and generate novel chemical entities with broad therapeutic potential
POTENTIAL THERAPEUTIC APPLICATIONS FOR ADVANCED ANALOGUES
●
●
Avoid potentially toxic metabolites
Moderate stimulatory & euphoric effects
●
●
Faster-acting compounds
Fewer drug-drug interactions
Emyria 2023
24
MDMA-INSPIRED DRUG DISCOVERY | WORKFLOW
with
NEW DRUG DISCOVERY
Take MDMA
as inspiration
Advanced
screening
Design & synthesise
new analogues
Prioritise
indications
Mental health
(Next-gen MDMA)
Proprietary analogue library
>140 novel chemical
●
●
●
●
●
Pharmacology (target) screens
Safety screens
Behavioural studies
Metabolism assays
Peripheral effects
Movement disorders
(Neuro treatments)
Non-neurological
(Fibrotic diseases)
entities and growing
Emyria 2023
25
MDMA-INSPIRED DRUG DISCOVERY | MULTIPLE $B OPPORTUNITIES
Clinical focus
Treatment Resistant
PTSD
(5% adults, 30-50% treatment
resistant)
Costs of $25B/year
L-DOPA induced dyskinesia in
Parkinson’s Disease
(40% of PD patients at 4 years of
treatment)
Costs of $1B/year
Role of MDMA?
MDMA increases feelings of
compassion and sociability
while reducing fear &
defensiveness.
Phase 3 trials have shown
MDMA-assisted therapy
can have a profound
benefit [1]
MDMA has been shown to
improve the “on-time’
(beneficial effects) of
L-DOPA but has numerous,
unwanted side-effects [2]
Fibrotic disease
Some analogues can
induce fibrosis.
Costs of $3B/year
Can MDMA analogues be
developed to reduce it?
(1.2M patients globally)
Goals for analogue program
Early proof-of-concept?
Faster-acting MDMA with improved
tolerability can increase the potential
pool of patients with potential to
benefit
Sub-set of analogues show
faster rates of metabolism,
Advanced screening
to identify rapidly
metabolised
compounds
Gold-standard preclinical model
demonstrates analogues can
increase on-time by 200%.
Advance new
compounds
Remove the “high” from MDMA
while preserving beneficial effects on
movement disorders.
Identify compounds with 5HT2B
antagonism (a known target for
anti-fibrosis medicines)
C/W recently approved PBS
drug (Ongentys) which
increases on-time by 1hr/24hrs
Cell assays demonstrate
reduced collagen deposition at
test concentrations.
1. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Nature Medicine. 2021 Jun;27(6):1025-33
What’s next?
Long-term safety
and tolerability
studies
Further
proof-of-concept
studies to identify
lead compounds
Emyria 2023
26
MDMA ANALOGUE HIGHLIGHT | FASTER-ACTING MDMA
MDMA-INSPIRED MEDICINES
Potential Target: MDMA-ASSISTED THERAPY FOR MENTAL HEALTH
Recent in vitro metabolic studies of Emyria’s analogues demonstrate that our library has compounds with diverse half-lives,
suggesting it may be possible to generate MDMA analogues with much faster, and slower onset of action.
Representative from
long-acting family
~180 mins
Half-life as measured in
human liver microsomes
MDMA
~76 mins
Potentially shorter-acting
analogue compared to MDMA
Note: These in vitro studies approximate
liver-led metabolism of drugs. Other
potential metabolic pathways (and other
clearance pathways) not represented in
microsomes are not evaluated.
Representative from
short-acting family
~<8 mins
Select compounds from
Emyria’s MDMA Analogue Library
NEXT STEPS:
●
Functional assays to identify novel compounds most like MDMA
●
Further in vitro metabolic screening to approximate half-life
Emyria 2023
27
MDMA-INSPIRED DRUG DISCOVERY | WHAT’S NEXT?
with
NEW DRUG DISCOVERY
IN THE NEXT 12 MONTHS, EMYRIA INTENDS TO:
●
DELIVER RESULTS from multiple preclinical programs on select MDMA analogues
●
SELECT LEADS by proof-of-concept efficacy studies in animal models
●
EXPAND the MDMA-analogue library
●
FILE additional patent families and pursue commercialisation discussions
MDMA-A
Hit-to-lead
Toxicology
Lead Selection & Dose
Form Development
Phase 1
Clinical Trials
Emyria 2023
28
INVESTMENT HIGHLIGHTS
1
Proprietary
formulations of
Ultra-Pure CBD
First dose form in
Phase 3 trials
Platform is
partnership ready
No THC or impurities
High bioavailability
low dose variability &
slower release
Supports multiple
indications
4
3
2
Proprietary Real
World Data (RWD)
engine
Emyria’s clinical
service, Emerald
Clinics, has gathered
the world’s largest
data set with
patients guiding
indication selection,
cannabinoid dose
form development
and pivotal clinical
trial designs. Will
now be applied to
MDMA therapies
MDMA now
recognised as
“medicine”
Changing
regulatory
environment
creates opportunity
to establish a
national network to
provide data that
can support the
MDMA analogue
program
Substantial
R&D pipeline
One of world’s
largest MDMA
analogue libraries novel, small, stable,
brain-penetrating
and neuroactive
molecules with
potential to become
novel
neuropsychiatric
treatments.
5
World-class
team with
multiple FDA
registrations
Emyria’s in-house
expertise covers
drug development,
clinical trials, drug
registration, data
analysis and
patient care.
Emyria 2023
29
CONTACT INFORMATION
Michael Winlo
Investors
Media
General
mwinlo@emyria.com
investors@emyria.com
media@emyria.com
info@emyria.com
Share your feedback
Discover